625 related articles for article (PubMed ID: 37491263)
1. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
3. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
4. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J
Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488
[TBL] [Abstract][Full Text] [Related]
5. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
6. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Virus-Driven Biotherapies from Bench to Bedside.
Duan S; Wang S; Qiao L; Yu X; Wang N; Chen L; Zhang X; Zhao X; Liu H; Wang T; Wu Y; Li N; Liu F
Small; 2023 Jun; 19(23):e2206948. PubMed ID: 36879416
[TBL] [Abstract][Full Text] [Related]
8. Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
[TBL] [Abstract][Full Text] [Related]
9. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
Zhang S; Rabkin SD
Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
[No Abstract] [Full Text] [Related]
10. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
11. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
[TBL] [Abstract][Full Text] [Related]
13. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
14. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
16. The two-faces of NK cells in oncolytic virotherapy.
Marotel M; Hasim MS; Hagerman A; Ardolino M
Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
[TBL] [Abstract][Full Text] [Related]
17. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
19. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.
Ripp J; Hentzen S; Saeed A
Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
